引言
慢性阻塞性肺疾病 (COPD) 是全球公共卫生领域的重大挑战,具有高发病率且死亡率逐年上升。因其病理机制复杂,管理和治疗难度较大。尽管当前已有一系列常规治疗手段,如支气管扩张剂和吸入性糖皮质激素 (ICS),但并非所有患者都对这些药物产生有效反应。
参考文献:
[1]Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. The Lancet Respiratory Medicine, 2019, 7(9): 745-756.
[2]Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respiratory Research, 2010, 11: 10. PMID: 20109213.
[3]The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS ONE, 2014, 9(8): e105609.